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Artemisinin-based combination therapy (ACT) is the first-line therapy in most malaria endemic 
countries. An impressive 47% reduction in the global mortality rate between 2000 and 2013 
has been achieved by ACT and artemisinin (ART) monotherapy. However, artemisinin 
resistance (AR) by Plasmodium falciparum(P. falciparum) is now prevalent across south-east 
Asia (SEA). AR is indicated by delayed parasite clearance of more than 3 days after standard 
ART treatment and reduced in vitrosusceptibility. Recent work has shown association of AR 
with mutations in the propeller domain of the kelch gene on chromosome 13 
(PF3D7_1343700, k13gene) of P. falciparum. The C580Y mutation of thek13gene is highly 
prevalent in Cambodia, Myanmar and eastern and western Thailand, while the F446I mutation 
is predominant in the China-Myanmar border regions as well as in Myanmar. AR has not 
reached India and Africa, where non-synonymous mutations not associated with delayed 
parasite clearance are present. Because the location of Myanmar is central between SEA and 
Africa, a country-specific strategy for Myanmar Artemisinin Resistance Containment (MARC) 
is necessary. Moreover, regular periodic tracking of prevalent molecular determinants such as 
C580Y and F446I mutations will be beneficial. 
 
